Fínecare™ 2019-nCoV RBD Antibody Test

Human Cell Membrane



RBD (receptor binding domain) of 2019-nCoV virus S1 protein is the region that binds to the ACE2 receptor on human cells as the first step of virus invading.

SPECIFICATION



Catalog No.	W290
Shelf Life	24 Months
Storage Condition	4~30 °C
Sample Type	Fingerstick whole blood, venipuncture whole blood, serum or plasma
Sample Volume	20 μL
Reaction Time	15 minutes

Infecting

APPLICATION



Vaccine efficacy evaluation



Measure immune response



Convalescent plasma therapy



2019-nCoV

Spike Protein

Neutralizing

Antibody

Infection


Blocked

2019-nCoV

Epidemiological survey

OPERATION PROCEDURE

SOP for fingerstick whole blood:



RESULT INTERPRETATION

	RFU Results	Result	Dilution Titer	Test Result Interpretation
	<1 AU/mL	Negative	<1:20	Neutralizing antibodies for 2019-nCoV are not detected at 50% virus neutralization.
	1~20 AU/mL	Positive (Low titer)	1:20~1:160	Low neutralizing antibodies for 2019-nCoV are detected at 50% virus neutralization.
	>20 AU/mL	Positive (High titer)	>1:160	High neutralizing antibodies for 2019-nCoV are detected at 50% virus neutralization.

APPLICABLE ANALYZERS



• Small size and portable Instant Results



•21-hours stand-by time



Finecare TM III Plus (FS-205)

- High throughput, 20 channels, 100 t/h
- ·Semi-automatic, less manual operation





